THE proposal to amend Statutory Instrument 330 of 2000 has been framed as an effort to address potential conflicts of interest within Zimbabwe’s healthcare system. The intention is understandable. The implications, however, deserve careful examination.
At the heart of the proposal is a plan to prohibit medical aid societies from owning, managing or operating healthcare facilities and to require the disposal of existing interests within a prescribed period.
The central question is whether this structural intervention will improve access, affordability and quality of care for patients — or inadvertently weaken them.
The position paper submitted by several medical aid societies argues that there is insufficient evidence that vertically integrated models have, in themselves, caused consumer harm in Zimbabwe. It contends that funders entered service provision largely in response to persistent market challenges, including tariff unpredictability, provider shortages and barriers to affordable care.
Whether one agrees with that assessment or not, it raises legitimate questions that warrant consideration before irreversible reforms are implemented.
The submission notes that a significant proportion of healthcare services utilised by medical aid members continue to be accessed through independent providers. If accurate, this would suggest that society-owned facilities coexist with, rather than replace, broader provider networks.
The concern raised by funders is that mandatory divestiture could have unintended consequences.
These include the possibility of distressed asset sales, reduced investment capacity, pressure on medical aid balance sheets and the eventual transfer of additional costs to members through higher contributions or increased out-of-pocket expenses.
The irony is difficult to ignore: a reform intended to protect healthcare consumers could, if poorly calibrated, leave those same consumers facing reduced affordability.
This debate is not simply about ownership structures. It is about outcomes.
Zimbabwe’s Constitution recognises the right to access basic healthcare services. Any regulatory intervention affecting the health sector should therefore be assessed against a straightforward public-interest test: Will it expand access? Will it improve affordability? Will it strengthen system resilience? Will it protect patients?
If the answer is uncertain, caution becomes a legitimate policy position rather than resistance to reform.
None of this suggests that concerns around insurer-provider integration should be dismissed.
Conflicts of interest can arise in any healthcare system and require effective oversight. The issue is whether prohibition is the most proportionate response.
Alternative approaches exist. Enhanced governance requirements, transparent related-party disclosures, independent audits, open-network provisions, tariff oversight and competition regulation could address many of the identified risks while preserving healthcare capacity and patient choice.
International experience generally favours targeted regulation over blanket prohibitions, recognising that integrated models can produce both risks and benefits depending on the market context.
Zimbabwe’s healthcare sector operates within a constrained environment characterised by limited medical aid coverage and significant affordability challenges. In such circumstances, major reforms should be guided not only by principle, but by evidence, stakeholder consultation and a rigorous assessment of likely consequences.
Healthcare policy should ultimately be judged by its effect on the patient.
Before dismantling existing arrangements, policymakers must be satisfied that what replaces them will demonstrably improve access, affordability and quality of care.
If that case has not yet been made, then further consultation and evidence-based review may be the wiser course.